



QuantiFERON-TB Gold Plus

Client Communication

Offering our clients state-of-the-art testing is part of Clinical Labs of Hawaii’s commitment to excellence.

Effective 2/4/2019, Clinical Labs of Hawaii is pleased to announce the introduction of QuantiFERON®-TB Gold Plus (QFT-Plus) assay, which offers optimized analyses with tuberculosis (TB)-specific antigens that elicit both CD4+ and CD8+ T-cell responses.

In the United States, 13 million individuals are believed to silently carry latent TB infection¹. Without treatment, they are at risk for developing active TB disease. Hawaii experiences the highest rate of TB in the U.S. – nearly 3 times the nation-wide average².

The CDC recommends Interferon-gamma Release Assays (IGRA)s, like QFT-Plus, for the majority of the U.S. testing population. IGRAs are preferred for TB testing in most risk groups, including³:

- Those likely to be infected with TB
- Anyone with low or intermediate risk of disease progression
- Those for whom it has been decided that testing for latent TB infection is warranted

The single Lithium Heparin tube collection offers the most ease and convenience and is available at any of our Patient Service Center (PSC) locations.

Order Code/Test Name	QUANTB (3527)/QuantiFERON®-TB Gold Plus 1
Test Method	Enzyme-Linked Immunosorbent Assay (ELISA)
Specimen Requirement	5.0 mL Whole Blood Lithium Heparin (No Gel-Dark Green top)
Stability	Room temperature: 3 hours Refrigerated: 2 days
Collection	Oahu: Sun-Sat, Neighbor Islands: Mon-Fri
Performed	Sun-Sat
Reported	1-2 days
Reference Interval	Negative
CPT Code	86480

References:

1. Houben, R.M. and Dodd, P.J. (2016) The global burden of latent Tuberculosis infection: a re-estimation using mathematical modeling. *PLoS Med.* 13 e1002152
2. Stewart, R.J. et al. (2018) Tuberculosis – United States, 2017. *MMWR* 67, 317-323.
3. Salinas, J.L., et al (2016) Leveling of Tuberculosis Incidence- United States; 2013-2015. *MMWR* 65, 273-278.